Press Releases
Sarepta Therapeutics gazes FDA approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53
Sarepta Therapeutics, Inc , a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. ...
News
Gilead Sciences appoints John McHutchison, MD, Appointed Chief Scientific Officer and Andrew Cheng, MD, PhD, Appointed Chief Medical Officer
Gilead Sciences, Inc. announced that Norbert Bischofberger, PhD, has decided to step down from his role as Executive Vice President, Research and Development and...
News
Novartis changes its executive committees to align with its strategic goals
Novartis announced changes to its senior leadership team to support the implementation of its strategic priorities. Bertrand Bodson, Chief Digital Officer, Steffen Lang, Global...
Press Releases
Largest Real-World Data Analysis Reveals Findings Of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Bristol-Myers Squibb Company and Pfizer Inc. will present findings from a real-world data (RWD) analysis titled, Comparison of Effectiveness, Safety, and the Net Clinical...
News
Recipharm completes Blow-fill-seal expansion at Kaysersberg facility
Recipharm, the contract development and manufacturing organisation (CDMO), announces its new Blow-fill-seal machinery is now operational following a substantial investment last year at its...
Press Releases
Nanologicaand Sterling partnership furthers new business venture
Nanologica AB (publ) has entered into a service agreement with global contract development and manufacturing organisation (CDMO) Sterling Pharma Solutions for the large-scale production...
Clinical Trials
Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study Of ALXN1210 In Complement Inhibitor Treatment-Naïve Patients With Paroxysmal Nocturnal Hemoglobinuria
Alexion Pharmaceuticals, Inc. announced that the pivotal Phase 3 study of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, demonstrated non-inferiority to Soliris® (eculizumab)...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read